As ri­vals look to carve up its block­buster rev­enue, No­var­tis’ Cosen­tyx reg­is­ters re­mark­ably con­sis­tent ef­fect for pso­ri­a­sis

A decade af­ter the very first pso­ri­a­sis pa­tient was treat­ed with Cosen­tyx (se­cuk­inum­ab), No­var­tis is rolling out a fresh set of da­ta un­der­scor­ing just how …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER